TRIMETHAPHAN CAMSYLATE
Arfonad (trimethaphan camsylate) is a small molecule pharmaceutical. Trimethaphan camsylate was first approved as Arfonad on 1982-01-01. It is used to treat aortic aneurysm, malignant hypertension, and pulmonary edema in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| aortic aneurysm | EFO_0001666 | D001014 | I71.9 |
| pulmonary edema | EFO_1001134 | D011654 | J81 |
| malignant hypertension | EFO_1001031 | D006974 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 5 | — | — | — | 2 | 7 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | — | 1 | 3 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | 1 | 2 |
| Multiple system atrophy | D019578 | — | — | 2 | — | — | — | — | 2 |
| Essential hypertension | D000075222 | — | I10 | 1 | — | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | — | — | 1 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | 1 | — | — | — | — | 1 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | — | — | — | — | 1 |
| Fatigue | D005221 | — | R53.83 | 1 | — | — | — | — | 1 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIMETHAPHAN CAMSYLATE |
| INN | trimetaphan camsilate |
| Description | Trimethaphan camsylate is the (S)-camphorsulfonate salt of trimethaphan. It has a role as an antihypertensive agent. It contains a trimethaphan and a (S)-camphorsulfonate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)C2CCC1(CS(=O)(=O)[O-])C(=O)C2.O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 68-91-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1245 |
| ChEBI ID | — |
| PubChem CID | 44602409 |
| DrugBank | DBSALT001381 |
| UNII ID | 8W556014K9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 306 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use